- Home
- MGRX vs ALLR Comparison
MGRX vs ALLR Comparison
Compare MGRX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- ALLR
- Stock Information
- Founded
- MGRX 2021
- ALLR 2004
- Country
- MGRX United States
- ALLR United States
- Employees
- MGRX N/A
- ALLR N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- ALLR Health Care
- Exchange
- MGRX Nasdaq
- ALLR Nasdaq
- Market Cap
- MGRX 12.3M
- ALLR 4.7M
- IPO Year
- MGRX 2023
- ALLR N/A
- Fundamental
- Price
- MGRX $4.04
- ALLR $0.90
- Analyst Decision
- MGRX
- ALLR
- Analyst Count
- MGRX 0
- ALLR 0
- Target Price
- MGRX N/A
- ALLR N/A
- AVG Volume (30 Days)
- MGRX 79.8K
- ALLR 2.4M
- Earning Date
- MGRX 03-31-2025
- ALLR 03-25-2025
- Dividend Yield
- MGRX N/A
- ALLR N/A
- EPS Growth
- MGRX N/A
- ALLR N/A
- EPS
- MGRX N/A
- ALLR N/A
- Revenue
- MGRX $755,000.00
- ALLR N/A
- Revenue This Year
- MGRX N/A
- ALLR N/A
- Revenue Next Year
- MGRX N/A
- ALLR N/A
- P/E Ratio
- MGRX N/A
- ALLR N/A
- Revenue Growth
- MGRX 52.20
- ALLR N/A
- 52 Week Low
- MGRX $2.07
- ALLR $0.68
- 52 Week High
- MGRX $16.80
- ALLR $231.00
- Technical
- Relative Strength Index (RSI)
- MGRX 48.24
- ALLR 44.17
- Support Level
- MGRX $3.59
- ALLR $1.00
- Resistance Level
- MGRX $5.33
- ALLR $1.24
- Average True Range (ATR)
- MGRX 0.58
- ALLR 0.14
- MACD
- MGRX -0.09
- ALLR 0.02
- Stochastic Oscillator
- MGRX 26.07
- ALLR 40.02
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.